Success Metrics

Clinical Success Rate
33.3%

Based on 3 completed trials

Completion Rate
33%(3/9)
Active Trials
1(6%)
Results Posted
133%(4 trials)
Terminated
6(35%)

Phase Distribution

Ph phase_3
4
24%
Ph not_applicable
10
59%
Ph phase_2
1
6%
Ph phase_1
1
6%
Ph phase_4
1
6%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
1(5.9%)
Phase 3Large-scale testing
4(23.5%)
Phase 4Post-market surveillance
1(5.9%)
N/ANon-phased studies
10(58.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

3 of 9 finished

Non-Completion Rate

66.7%

6 ended early

Currently Active

1

trials recruiting

Total Trials

17

all time

Status Distribution
Active(2)
Completed(3)
Terminated(6)
Other(6)

Detailed Status

unknown6
Terminated6
Completed3
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.9%)
Phase 21 (5.9%)
Phase 34 (23.5%)
Phase 41 (5.9%)
N/A10 (58.8%)

Trials by Status

unknown635%
not_yet_recruiting16%
recruiting16%
completed318%
terminated635%

Recent Activity

1 active trials
Showing 5 of 17
not_yet_recruitingphase_3

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

NCT07202897
terminatednot_applicable

Large Stroke Therapy Evaluation

NCT03811769
terminatednot_applicable

Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease

NCT05622500
recruitingnot_applicable

DTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage

NCT05891509
unknownnot_applicable

Minor Stroke Therapy Evaluation

NCT03796468
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07202897Phase 3

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Not Yet Recruiting
NCT03811769Not Applicable

Large Stroke Therapy Evaluation

Terminated
NCT05622500Not Applicable

Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease

Terminated
NCT05891509Not Applicable

DTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage

Recruiting
NCT03796468Not Applicable

Minor Stroke Therapy Evaluation

Unknown
NCT05174754Not Applicable

Response To Medical Therapy in Inflammatory Bowel Disease Patients Carrying-out a Prescribed Exercise Programme

Unknown
NCT02211495Not Applicable

ULCERS - Electrical Stimulation in Diabetic Foot Ulceration

Completed
NCT04276350Not Applicable

Efficacy of Acupuncture as a Treatment for Faecal Incontinence

Unknown
NCT03839953Not Applicable

Exercise Rehabilitation for Patients With Critical Limb Ischemia After Revascularization

Unknown
NCT02136537Not Applicable

Electrical Stimulation in Peripheral Arterial Disease

Terminated
NCT01666132Phase 1

METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease

Terminated
NCT00056563Phase 3

Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial

Completed
NCT00742274Not Applicable

A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection

Completed
NCT01013623Phase 3

Stage IV Surgery Versus Best Medical Therapy

Terminated
NCT00029146Phase 3

Carotid Occlusion Surgery Study

Terminated
NCT00711984Phase 4

Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis

Unknown
NCT00201461Phase 2

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

Unknown

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17